Abbvie Inc (NYSE:ABBV)
| 110.53 Delayed Data As of Jan 15 |  +0.01 / +0.01%Today’s Change | 62.55 Today|||52-Week Range 113.41 | +3.15% Year-to-Date |
ABBV Regular Dividend: ABBV began trading ex-dividend on 01/14/21. A $1.30 dividend will be paid to shareholders of record as of 01/15/21.
Latest ABBV News | Press Releases
| Editas (EDIT) Up More Than 100% in Past 3 Months: Here's Why Jan 18 / Zacks.com - Paid Partner Content | 3 Great Dividend Stocks That Are Simply Too Cheap to Ignore Jan 14 / MotleyFool.com - Paid Partner Content |
| The Biggest Drug Competition in 2021 (Hint: It Isn't COVID Vaccines) Jan 17 / MotleyFool.com - Paid Partner Content | AbbVie (ABBV) Inks Deal to Acquire Medical Device Company Jan 13 / Zacks.com - Paid Partner Content |
| 3 Green Flags for AbbVie in 2021 and 1 Red Flag Jan 15 / MotleyFool.com - Paid Partner Content | These 3 Value Stocks Are Absurdly Cheap Right Now Jan 13 / MotleyFool.com - Paid Partner Content |
| 5 Top Healthcare Stocks for 2021 Jan 15 / StockNews.com - Paid Partner Content | 3 Dividend Aristocrats to Buy Right Now Jan 13 / MotleyFool.com - Paid Partner Content |
| AbbVie (ABBV) Dips More Than Broader Markets: What You Should Know Jan 14 / Zacks.com - Paid Partner Content | AbbVie (ABBV) Outpaces Stock Market Gains: What You Should Know Jan 12 / Zacks.com - Paid Partner Content |
Today’s Trading
| Previous close | 110.52 |
| Today’s open | 111.11 |
| Day’s range | 109.53 - 111.54 |
| Volume | 3,302 |
| Average volume (3 months) | 7,930,378 |
| Market cap | $195.1B |
Data as of 4:17pm ET, 01/15/2021
Growth & Valuation
| Earnings growth (last year) | +44.28% |
| Earnings growth (this year) | +17.29% |
| Earnings growth (next 5 years) | +5.71% |
| Revenue growth (last year) | +1.57% |
| P/E ratio | 23.8 |
| Price/Sales | 3.95 |
| Price/Book | -- |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| PFEPfizer | +0.00 | +0.01% |
| LLYEli Lilly and Co | +0.17 | +0.09% |
| MRKMerck | +1.21 | +1.47% |
| NVSNovartis | +1.01 | +1.07% |
Data as of 4:59pm ET, 01/15/2021
Financials
| Next reporting date | February 3, 2021 |
| EPS forecast (this quarter) | $2.86 |
| Annual revenue (last year) | $33.3B |
| Annual profit (last year) | $7.8B |
| Net profit margin | 23.57% |
Profile
Sector Health Technology |
Industry Pharmaceuticals: Major |
No executives to display |
Corporate headquarters North Chicago, Illinois |
Forecasts
